| Literature DB >> 25946248 |
Heloisa da Silveira Paro Pedro1, Susilene Maria Tonelli Nardi1, Maria Izabel Ferreira Pereira1, Rosângela Siqueira Oliveira2, Philip Noel Suffys3, Harrison Magdinier Gomes3, Amanda Juliane Finardi4, Eloise Brasil de Moraes4, Ida Maria Foschiani Dias Baptista4, Ricardo Luiz Dantas Machado5, Lilian Castiglioni5.
Abstract
Drug-resistant tuberculosis (TB) is a growing global threat. Approximately 450,000 people developed multidrug-resistant TB worldwide in 2012 and an estimated 170,000 people died from the disease. This paper describes the sociodemographic, clinical-epidemiological and bacteriological aspects of TB and correlates these features with the distribution of anti-TB drug resistance. Mycobacterium tuberculosis (MT) cultures and drug susceptibility testing were performed according to the BACTEC MGIT 960 method. The results demonstrated that MT strains from individuals who received treatment for TB and people who were infected with human immunodeficiency virus were more resistant to TB drugs compared to other individuals (p < 0.05). Approximately half of the individuals received supervised treatment, but most drug-resistant cases were positive for pulmonary TB and exhibited positive acid-fast bacilli smears, which are complicating factors for TB control programs. Primary healthcare is the ideal level for early disease detection, but tertiary healthcare is the most common entry point for patients into the system. These factors require special attention from healthcare managers and professionals to effectively control and monitor the spread of TB drug-resistant cases.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25946248 PMCID: PMC4489455 DOI: 10.1590/0074-02760140316
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN: 0074-0276 Impact factor: 2.743
Laboratory diagnostic results of clinical specimens from patients diagnosed with Mycobacterium tuberculosisa
| Tests | n (%) |
|---|---|
| Acid-fast bacilli smear | |
| Positive | 221 (63.5) |
| Negative | 127 (36.5) |
| Antibiotic susceptibility testing | |
| Susceptible | 317 (91.1) |
| Resistant | |
| Mono-resistant (n = 23) | |
| INH | 7 (2) |
| RMP | 4 (1.1) |
| PZA | - |
| SM | 12 (3.4) |
| EMB | - |
| Multidrug-resistant (n = 6) | |
| INH + RMP INH + RMP + PZA SM + INH + PZA + RMP | 2 (0.6) 3 (0.9) 1 (0.3) |
| Poly-resistant (n = 2) | |
| SM + INH | 2 (0.6) |
| Total | 31 (8.9) |
a: n = 348; EMB: ethambutol; INH: isoniazid; PZA: pyrazinamide; RMP: rifampicin; SM: streptomycin.
Distribution of the main sociodemographic, epidemiological and clinical characteristics associated with drug resistance
| Characteristic | Susceptible | Resistant | OR | 95% CI | p | Total |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 269 | 26 | 0.92 | 0.33-2.53 | 0.900 | 295 |
| Female | 48 | 5 | 53 | |||
| 348 | ||||||
| Age group (years) | ||||||
| 15-45 | 230 | 23 | 0.91 | 0.39-2.13 | 0.987 | 253 |
| > 45 | 87 | 8 | 95 | |||
| 348 | ||||||
| Educational level | ||||||
| < 8 | 164 | 12 | 1.04 | 0.39-2.64 | 1.000 | 176 |
| ≥ 8 | 105 | 8 | 113 | |||
| 289 | ||||||
| HIV | ||||||
| Negative | 248 | 17 | 3.36 | 1.51-7.47 | 0.004 | 265 |
| Positive | 52 | 12 | 64 | |||
| 329 | ||||||
| AFB smear | ||||||
| Negative | 117 | 10 | 1.22 | 0.55-2.69 | 0.698 | 127 |
| Positive | 200 | 21 | 221 | |||
| 348 | ||||||
| Deprivation of liberty | ||||||
| No | 174 | 21 | 0.33 | 0.12-0.91 | 0.035 | 191 |
| Yes | 124 | 5 | 129 | |||
| 320 | ||||||
| Alcoholism | ||||||
| No | 225 | 20 | 1.30 | 0.58-2.90 | 0.526 | 245 |
| Yes | 86 | 10 | 96 | |||
| 341 | ||||||
| Tobacco smoking | ||||||
| No | 246 | 23 | 1.16 | 0.48-2.84 | 0.813 | 269 |
| Yes | 64 | 7 | 71 | |||
| 340 | ||||||
| Drug addiction | ||||||
| No | 256 | 28 | 0.32 | 0.07-1.41 | 0.133 | 284 |
| Yes | 56 | 2 | 58 | |||
| 342 | ||||||
| Clinical presentation | ||||||
| Pulmonary | 304 | 31 | 2.66 | 0.00-2.66 | 0.165 | 335 |
| Extrapulmonary | 13 | - | 13 | |||
| 348 | ||||||
| Previous TB treatment | ||||||
| No | 259 | 14 | 5.66 | 2.57-12.47 | < 0.001 | 273 |
| Yes | 49 | 15 | 64 | |||
| 337 | ||||||
| Type of treatment | ||||||
| Supervised | 180 | 15 | 0.79 | 0.31-2.00 | 0.818 | 195 |
| Self-administered | 106 | 7 | 113 | |||
| 308 |
a: data not available at TB Surveillance System of São Paulo State; AFB: acid-fast bacilli; CI: confidence interval; HIV: human immunodeficiency virus; OR: odds ratio; TB: tuberculosis.